LMR Partners’s AstraZeneca AZN Stock Holding History

LMR Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,850	Closed	-$2.36M	–	1463
2025 Q4	$2.36M	Hold	12,850	–	–	﹤0.01%	772
2025 Q3	$1.97M	Hold	12,850	–	–	0.01%	737
2025 Q2	$1.8M	Sell	12,850 -12,250	-49%	-$1.72M	0.01%	673
2025 Q1	$3.69M	Buy	25,100 +100	+0.4%	+$14.5K	0.03%	508
2024 Q4	$3.28M	Hold	25,000	–	–	0.03%	481
2024 Q3	$3.9M	Hold	25,000	–	–	0.03%	428
2024 Q2	$3.9M	Buy	+25,000	New	+$3.76M	0.03%	385
2023 Q4	–	Sell	-7,500	Closed	-$1.02M	–	997
2023 Q3	$1.02M	Sell	7,500 -173,950	-96%	-$23.8M	0.01%	483
2023 Q2	$26M	Buy	+181,450	New	+$26.7M	0.29%	84

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

LMR Partners's AZN Position: Q1 2026 in Review

LMR Partners reduced its AstraZeneca (AZN) stake by 97% in Q1 2026, selling an estimated $133M and leaving 20,425 shares worth $4.03M. The position accounts for 0.01% of the portfolio, ranked #703.

LMR Partners first reported a position in AZN in Q2 2020 and has held it in 17 quarters since. The position peaked at $130M in Q4 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

LMR Partners held 20,425 shares of AstraZeneca worth $4.03M as of Q1 2026.
LMR Partners sold 688,024 AstraZeneca shares in Q1 2026, an estimated $133M.
AstraZeneca made up 0.01% of LMR Partners's portfolio in Q1 2026, its #703 holding.
LMR Partners first reported a position in AstraZeneca in Q2 2020 and has held it in 17 quarters since.
LMR Partners's AstraZeneca position peaked at $130M in Q4 2025.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.